Evidence map›Paper›PMID 35950852›Full record

ArticleCurrent protocols2022

Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs.

Achchhe Patel, Grazia Iannello, Alejandro Garcia Diaz, Dario Sirabella, Vidhu Thaker, Barbara Corneo

Erratum issuedOpen access · hybridAbstract readCase Reports
In one paragraph

Article in Current protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Rational Targeting and gRNA Design for Enhancing Quorum Quenching inComputational and structural biotechnology journal · 2026
    Article
  6. RNA helicase DDX3X promotes NK cell survival by supporting MCL1 expression.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Article
  7. Article
  8. Article
  9. Coenzyme QFree radical biology & medicine · 2025
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Achchhe PatelColumbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.
Grazia IannelloColumbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.
Alejandro Garcia DiazSpanish National Cancer Research Center, Madrid, Spain.
Dario SirabellaColumbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.
Vidhu ThakerDivision of Molecular Genetics, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York.
Barbara CorneoColumbia Stem Cell Initiative, Stem Cell Core, Columbia University Irving Medical Center, New York, New York.
New York Stem Cell Foundation · USCentro de Investigación del Cáncer · ESColumbia University Irving Medical Center · US

Funding

RESEARCH TRAININGP30DK026687 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI Anthony W Ferrante, DYMPNA GALLAGHER · 1986 to 2026
$33.0M
NIDDK NIH HHS P30 DK026687
6 · The paper itself

Abstract

The CRISPR system is an adaptive defense mechanism used by bacteria and archaea against viruses and plasmids. The discovery of the CRISPR-associated protein Cas9 and its RNA-guided cleavage mechanism marked the beginning of a new era in genomic engineering by enabling the editing of a target region in the genome. Gene-edited cells or mice can be used as models for understanding human diseases. Given its high impact in functional genomic experiments on different model systems, several CRISPR/Cas9 protocols have been generated in the past years. The technique uses a straightforward "cut and stitch" mechanism, but requires an accurate step-by-step design. One of the key points is the use of an efficient programmable guide RNA to increase the rate of success in obtaining gene-specific edited clones. Here, we describe an efficient editing protocol using a ribonucleotide protein (RNP) complex for homology-directed repair (HDR)-based correction of a point mutation in an induced pluripotent stem cell (iPSC) line generated from a 14-year-old patient with severe early-onset obesity carrying a de novo variant of ARNT2. The resulting isogenic iPSC line, named CUIMCi003-A-1, has a normal karyotype, expresses stemness markers, and can be differentiated into progenies from all three germ layers. We provide a detailed workflow for designing a single guide RNA and donor DNA, and for isolating clonal human iPSCs edited with the desired modification. This article also focuses on parameters to consider when selecting reagents for CRISPR/Cas9 gene editing after testing their efficiency with in silico tools. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Design of sgRNAs and PCR primers Basic Protocol 2: Testing the efficiency of sgRNAs Basic Protocol 3: Design of template or donor DNA Basic Protocol 4: Targeted gene editing Basic Protocol 5: Selection of positive clones Basic Protocol 6: Freezing, thawing, and expansion of cells Basic Protocol 7: Characterization of edited cell lines.

Indexed as

Gene EditingInduced Pluripotent Stem CellsAdolescentAnimalsCRISPR-Cas SystemsDNAHumansMiceObesityRNA, Guide, CRISPR-Cas SystemsDNARNA, Guide, CRISPR-Cas Systemsanalysis webtoolsCRISPR/Cas9gene editinghiPSC

Identifiers

PMID35950852
PMCPMC9377717
OpenAlexW4290805916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.